Brief Description
The study is evaluating the safety and effectiveness of an investigational, targeted C3 inhibitor called pegcetacoplan in adults who have C3G or IC-MPGN recurrence after kidney transplant
Trial Physician / Study Coordinator
Elizabeth Carfioli
Estimated Enrollment
12 patients
Estimated End Date
End of enrollment – December 2021; End of study – September 2022
Trial is for people with
Diagnosis of C3G or IC-MPGN that has recurred after a kidney transplant. In addition, participants must be: - at least 18 years of ...
Study Goal
The NOBLE study is exploring whether pegcetacoplan has an effect on the build up of the complement protein C3 in the kidney, that ...
What is involved for the patient?
After completing a screening period, study participants will be randomly assigned (randomized) to one of two treatment ...
About the drug or intervention
Pegcetacoplan is an investigational, targeted C3 inhibitor. It is administered via a needle, under the skin (subcutaneous), twice ...